Aurobindo gets USFDA nod for Trandolapril

Mumbai, June 15: Pharma major Aurobindo today announced they have received approval from the US Food and Drug Administration (FDA) for Trandolapril tablets used for treating hypertension.

Trandolopril is an ACE inhibitor and is dosed once a day. It is also employed in combination with diuretics or other calcium channel blockers due to its beneficial synergy. It is a better choice in diabetic hypertensives as it helps in slowing down the onset of nephropathy besides performing it's primary role of regulating blood pressure.

This is the fourth anti-hypertensive of the Company bagging USFDA's nod, the pharma major said and added that Trandolapril is the generic equivalent of Abbott's Mavik tablets.

Trandolopril tablets currently enjoy a market share of around USD 50 million in the USA.

UNI